News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
For the quarter ended June 2026, Viatris (VTRS) reported revenue of $3.76 billion, up 4.9% over the same period last year. EPS came in at $0.69, compared to $0.62 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $3.68 …
Sharemaestro market context Trend signal active 52 weeks +56.5%Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …
Sharemaestro market context Trend signal active 52 weeks +56.5%Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026 Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street's expectations in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year's revenue to be around $14.75 billion, …
Sharemaestro market context Trend signal active 52 weeks +56.5%Viatris Inc. (VTRS) reported Q2 adjusted EPS of $0.69 per share, surpassing the FactSet estimate of $0.60. The company also announced Q2 revenue of $3.76 billion, exceeding the FactSet estimate of $3.68 billion.
Viatris Inc. announced strong second-quarter 2026 financial results, with total revenues of $3.8 billion, a 5% reported growth, and Adjusted EBITDA of $1.2 billion, up 8% operationally. The company raised its 2026 financial guidance midpoints, returned approximately $550 million to shareholders, and reduced its …
Sharemaestro market context Trend signal active 52 weeks +56.5%Harrow, Inc. NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from …
Orthopediatrics Corp (KIDS) reported its Q2 2026 financial results, with revenue increasing to $70.5 million from $61.1 million year-over-year. The company posted a net loss of $7.16 million and diluted EPS of $(0.30), largely consistent with the previous year. Key growth drivers included Trauma …
Viatris Inc. is preparing to announce its second-quarter earnings, with analysts anticipating $0.61 EPS on $3.67 billion in revenue. Investors are keenly watching whether the company's recent pipeline successes, such as FDA acceptance for fast-acting meloxicam and positive Phase 3 results for VR-205, can …
In its upcoming report, Viatris (VTRS) is predicted by Wall Street analysts to post quarterly earnings of $0.62 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $3.68 billion, representing a year-over-year increase of 2.6%. The …
Sharemaestro market context Trend signal active 52 weeks +56.5%Analysts have raised the 12-month average price target for OrthoPediatrics Corp. stock from $25 to $26.67, with individual forecasts ranging from $22 to $35 per share. This new target implies a potential upside of approximately 28% from the Aug. 4 closing price. The consensus …
Needham has increased its target price for ORTHOPEDIATRICS CORP (KIDS.O) to $35 from the previous $30. This adjustment indicates a more optimistic outlook by the analyst firm regarding the company's future stock performance. The report was issued by Reuters.
OrthoPediatrics reported record Q2 2026 net revenue of $70.5 million, marking a 15% increase year-over-year, primarily driven by strong growth in Trauma and Deformity products and international sales. The company also achieved a record adjusted EBITDA of $6.8 million and significantly improved free cash …
OrthoPediatrics Corp. (KIDS) reported a Q2 loss of $7.2 million, or 30 cents per share, which adjusted to 26 cents per share. The medical device maker posted revenue of $29.5 million for the quarter and expects full-year revenue to be between $125 million and …
OrthoPediatrics Corp. (NASDAQ: KIDS) is projecting 2026 revenue between $265 million and $269 million, alongside an Adjusted EBITDA of approximately $25 million and roughly breakeven free cash flow. This outlook is detailed in an investor update that also highlights the company's focus on the …
OrthoPediatrics (Nasdaq: KIDS) reported record Q2 2026 revenue of $70.5 million, a 15% year-over-year increase, driven by strong growth in U.S. and international markets, particularly in its Trauma & Deformity segment. The company helped nearly 46,000 children and achieved a record adjusted EBITDA of …
OrthoPediatrics Corp. announced strong financial results for the second quarter of 2026, with record total revenue of $70.5 million, marking a 15% year-over-year increase, and record adjusted EBITDA of $6.8 million. The company helped nearly 46,000 children and significantly reduced free cash flow usage. …
Viatris (VTRS) is set to announce its second-quarter 2026 earnings on August 6th, with analysts expecting revenues of $3.68 billion and earnings per share of 62 cents. The company's performance will be influenced by factors such as geographical segment sales (Developed Markets, Emerging Markets, …
Sharemaestro market context Trend signal active 52 weeks +56.5%Image by Jakub Zerdzicki via Unsplash With a market cap of $20.5 billion, Viatris Inc. (VTRS) is a global healthcare company committed to empowering people worldwide to live healthier lives at every stage. With a diverse portfolio spanning generics, established brands, and innovative medicines, …
Sharemaestro market context Trend signal active 52 weeks +56.5%Viatris Inc. announced that its Board of Directors has declared a quarterly dividend of $0.12 per share. This dividend will be paid to shareholders of record as of August 21, 2026, with the payment date set for September 16, 2026. The announcement was made …
Viatris Inc. (Nasdaq: VTRS) announced that its Board of Directors declared a quarterly dividend of $0.12 per share. The dividend is payable on September 16, 2026, to shareholders of record as of August 21, 2026. The company also included a section on forward-looking statements …
Sharemaestro market context Trend signal active 52 weeks +56.5%Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Viatris received U.S. FDA approval for its new combined hormonal contraceptive patch, Gwyn Lo. The product is a low dose estrogen contraceptive patch with data …
Viatris Inc. (Nasdaq: VTRS) announced it will present at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8 a.m. PT / 11 a.m. ET. Investors and the public can listen to the live webcast on the company's investor …
This article provides key metrics for the Viatris Inc. (PFE5282055) corporate bond, including its issuer, issue and maturity dates, outstanding amount, face value, and coupon rate. It also offers a brief overview of Viatris Inc.'s business operations and segments. The bond has an issue …
Viatris Inc. (VTRS) stock fell 1.13% on Friday, closing at $17.56, despite an overall positive trading session for the broader market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains. This marks the third consecutive day of losses for Viatris …
This article from Stock Traders Daily discusses the technical signals for Orthopediatrics Corp. (NASDAQ: KIDS) that institutions follow. It highlights strong near-term sentiment with neutral mid and long-term outlooks, noting compelling upside potential due to a lack of resistance levels above the current price. …
Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when Viatris (VTRS) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its …
Sharemaestro market context Trend signal active 52 weeks +56.5%Viatris (VTRS) recently received FDA approval for Gwyn Lo, a new weekly low-estrogen contraceptive patch, which is expected to diversify its product mix towards higher-margin, branded offerings. This approval supports the company's strategy to shift from a generics-heavy portfolio to more complex and branded …
Viatris Inc (VTRS) has a current risk assessment score of 8.80, placing it 21st out of 155 in the Pharmaceuticals industry. The company's beta of 0.89 indicates it tends to underperform during market uptrends but experiences smaller declines during downturns. The report details various …
OrthoPediatrics Corp. (NASDAQ: KIDS) has approximately 606 employees worldwide as of March 2026, marking a 13.6% growth from 2023. The company is actively hiring, with 45 active job postings in 2026, an 11.8% increase from 2025. The workforce is primarily concentrated in North America, …
Search by ticker symbol or company name and select a result to open its chart.